364 related articles for article (PubMed ID: 7861712)
1. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy.
Goodman WG; Ramirez JA; Belin TR; Chon Y; Gales B; Segre GV; Salusky IB
Kidney Int; 1994 Oct; 46(4):1160-6. PubMed ID: 7861712
[TBL] [Abstract][Full Text] [Related]
2. Evolution of secondary hyperparathyroidism during oral calcitriol therapy in pediatric renal osteodystrophy.
Goodman WG; Salusky IB
Contrib Nephrol; 1991; 90():189-95. PubMed ID: 1959345
[TBL] [Abstract][Full Text] [Related]
3. Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration.
Salusky IB; Kuizon BD; Belin TR; Ramirez JA; Gales B; Segre GV; Goodman WG
Kidney Int; 1998 Sep; 54(3):907-14. PubMed ID: 9734615
[TBL] [Abstract][Full Text] [Related]
4. Pulse oral versus pulse intraperitoneal calcitriol: a comparison of efficacy in the treatment of hyperparathyroidism and renal osteodystrophy in peritoneal dialysis patients.
Gadallah MF; Arora N; Torres C; Ramdeen G; Schaeffer-Pautz A; Moles K
Adv Perit Dial; 2000; 16():303-7. PubMed ID: 11045316
[TBL] [Abstract][Full Text] [Related]
5. Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD.
Kuizon BD; Goodman WG; Jüppner H; Boechat I; Nelson P; Gales B; Salusky IB
Kidney Int; 1998 Jan; 53(1):205-11. PubMed ID: 9453020
[TBL] [Abstract][Full Text] [Related]
6. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
7. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure.
Andress DL; Norris KC; Coburn JW; Slatopolsky EA; Sherrard DJ
N Engl J Med; 1989 Aug; 321(5):274-9. PubMed ID: 2631697
[TBL] [Abstract][Full Text] [Related]
8. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis.
Greenbaum LA; Grenda R; Qiu P; Restaino I; Wojtak A; Paredes A; Benador N; Melnick JZ; Williams LA; Salusky IB
Pediatr Nephrol; 2005 May; 20(5):622-30. PubMed ID: 15785941
[TBL] [Abstract][Full Text] [Related]
9. The renal bone diseases in children treated with dialysis.
Sanchez CP; Salusky IB
Adv Ren Replace Ther; 1996 Jan; 3(1):14-23. PubMed ID: 8620364
[TBL] [Abstract][Full Text] [Related]
10. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
Monier-Faugere MC; Geng Z; Friedler RM; Qi Q; Kubodera N; Slatopolsky E; Malluche HH
Kidney Int; 1999 Mar; 55(3):821-32. PubMed ID: 10027919
[TBL] [Abstract][Full Text] [Related]
11. Renal osteodystrophy in chronic renal failure.
Ho LT; Sprague SM
Semin Nephrol; 2002 Nov; 22(6):488-93. PubMed ID: 12430093
[TBL] [Abstract][Full Text] [Related]
12. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD.
Salusky IB; Ramirez JA; Oppenheim W; Gales B; Segre GV; Goodman WG
Kidney Int; 1994 Jan; 45(1):253-8. PubMed ID: 8127016
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal calcitriol in infants on peritoneal dialysis.
Cano FJ; Azocar MA; Guerrero JL; Delucchi MA; Lillo AM; Emilfork M; Rodríguez EE
Perit Dial Int; 2007; 27(6):681-6. PubMed ID: 17984431
[TBL] [Abstract][Full Text] [Related]
14. Serum magnesium concentration is an independent predictor of parathyroid hormone levels in peritoneal dialysis patients.
Navarro JF; Mora C; Macia M; Garcia J
Perit Dial Int; 1999; 19(5):455-61. PubMed ID: 11379859
[TBL] [Abstract][Full Text] [Related]
15. Intermittent calcitriol therapy and growth in children with chronic renal failure.
Kuizon BD; Salusky IB
Miner Electrolyte Metab; 1998; 24(4):290-5. PubMed ID: 9554570
[TBL] [Abstract][Full Text] [Related]
16. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.
Wesseling-Perry K; Pereira RC; Sahney S; Gales B; Wang HJ; Elashoff R; Jüppner H; Salusky IB
Kidney Int; 2011 Jan; 79(1):112-9. PubMed ID: 20861820
[TBL] [Abstract][Full Text] [Related]
17. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group.
Indridason OS; Quarles LD
Kidney Int; 2000 Jan; 57(1):282-92. PubMed ID: 10620210
[TBL] [Abstract][Full Text] [Related]
18. Renal bone disease in pediatric patients receiving treatment with maintenance peritoneal dialysis.
Salusky IB; Goodman WG
Child Nephrol Urol; 1991; 11(3):165-8. PubMed ID: 1777895
[TBL] [Abstract][Full Text] [Related]
19. Measurement of PTH fragments for assessment of renal bone disease in hemodialysis patients.
Fehr T; Garzoni D; Staub T; Binet I; Wüthrich RP
Kidney Blood Press Res; 2006; 29(3):175-81. PubMed ID: 16931896
[TBL] [Abstract][Full Text] [Related]
20. Implications of intermittent calcitriol therapy on growth and secondary hyperparathyroidism.
Salusky IB; Goodman WG; Kuizon BD
Pediatr Nephrol; 2000 Jul; 14(7):641-5. PubMed ID: 10912534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
